Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets

Elena I Sinauridze1, Dmitry A Kireev, Nadezhda Y Popenko

  • 1National Research Center for Hematology, Russian Academy of Medical Sciences, 4a Novyi Zykovskii proezd, Moscow 125167, Russia. helen@blood.ru

Insights

Platelet microparticles (PMPs) are significantly more procoagulant than activated platelets. Despite smaller surface areas, PMPs exhibit 50-100 times greater procoagulant activity, suggesting a key role in thrombosis.

Area of Science:

  • Hematology
  • Biochemistry
  • Thrombosis Research

Background:

  • Platelet microparticles (PMPs) are released from activated platelets and implicated in thrombotic events.
  • Previous studies characterized PMP procoagulant activity in artificial systems.
  • Elevated PMP levels in pathological states suggest a contribution to thrombosis.

Purpose of the Study:

  • To compare the procoagulant properties of activated platelets and PMPs.
  • To quantify differences in surface factor binding and thrombin generation potential.
  • To assess the procoagulant efficiency per unit surface area.

Main Methods:

  • In vitro hemostasis models were employed.
  • Flow cytometry quantified surface marker and bound factor densities.
  • Reaction-diffusion models and endogenous thrombin potential assays were performed.

Main Results:

  • PMPs showed significantly higher surface densities of phosphatidylserine, CD61, CD62P, and bound factor X compared to activated platelets.
  • Both spatial clot growth rate and endogenous thrombin potential increased with PMP and platelet concentration.
  • The procoagulant activity per PMP was comparable to that of an activated platelet, indicating higher surface procoagulancy for PMPs.

Conclusions:

  • PMP surfaces are 50- to 100-fold more procoagulant than activated platelet surfaces.
  • PMPs possess potent procoagulant capabilities, potentially exceeding those of activated platelets on a per-unit-area basis.
  • These findings highlight the critical role of PMPs in hemostasis and thrombosis.

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...